TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01274663
Drug: PF-05175157 or Placebo
Normalized name: PF-05175157
DrugBank: PF-05175157 (DB12096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
Study: NCT01274663
Drug: PF-05175157 or Placebo
Normalized name: PF-05175157
DrugBank: PF-05175157 (DB12096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
Study: NCT01304095
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
Study: NCT03057613
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg every 3 weeks for 16 weeks given by IV infusion
Study: NCT01710995
Drug: Zegerid
Normalized name: Zegerid
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01710995
Drug: Losec
Normalized name: Losec
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02341638
Drug: BMS-986141
Normalized name: BMS-986141
DrugBank: BMS-986141 (DB14942)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02341638
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02341638
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01829971
Drug: MRX34
Normalized name: Miravirsen
DrugBank: Miravirsen (DB12851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: micro RNA therapy
Study: NCT04087590
Drug: Formoterol-glycopyrronium co suspension (PT003)
Normalized name: formoterol / glycopyrronium
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
Study: NCT02453373
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate will be administered intravenously as needed to control shivering
Study: NCT02453373
Drug: tPA
Normalized name: tPA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tPA will be administered intravenously if indicated
Study: NCT02453373
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
Study: NCT02453373
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
Study: NCT02473640
Drug: SYN-004
Normalized name: .beta.-lactamase (synthetic bacillus licheniformis isoenzyme syn-004)
DrugBank: Ribaxamase (DB16311)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02473640
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02473640
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02472522
Drug: Ropivacaine + Dexmedetomidine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
Study: NCT02447055
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02447055
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02447055
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02447055
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02447055
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02254577
Drug: Endometrin® plus Progesterone in Oil (PIO)
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02254577
Drug: Progesterone in Oil (PIO) Only
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02453490
Drug: Raltitrexed-based chemotherapy
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
Study: NCT02609139
Drug: PF-06650833
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 400mg modified release tablets administered under fasted conditions
Study: NCT02609139
Drug: PF-06650833
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg modified release tablet administered under fasted conditions
Study: NCT02609139
Drug: PF-06650833
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg modified release tablet administered under fasted conditions
Study: NCT01970046
Drug: SP2086 50 mg q.d./Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~* Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks
Study: NCT02453490
Drug: Raltitrexed-based chemotherapy
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
Study: NCT01357655
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
Study: NCT01357655
Drug: BMS-833923
Normalized name: BMS-833923
DrugBank: BMS-833923 (DB16844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
Study: NCT02609139
Drug: PF-06650833
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 400mg modified release tablets administered with high fat meal food intake
Study: NCT02609139
Drug: PF-06650833
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg modified released tablet administered with high fat meal food intake
Study: NCT02609139
Drug: PF-06650833
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg modified release tablet administered with high fat meal food intake
Study: NCT00068575
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m\^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
Study: NCT00050154
Drug: ZARNESTRA, tipifarnib, R115777
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04289675
Drug: Interferon-Beta
Normalized name: Interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.
Study: NCT00868010
Drug: donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
Study: NCT00806247
Drug: tapentadol HCl
Normalized name: tapentadol HCl
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00453362
Drug: erlotinib HCl
Normalized name: erlotinib HCl
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets taken orally 150 mg/day.
Study: NCT03367754
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (immunoglobulin \[Ig\] G4 kappa isotype) that binds to PD-1, thus blocking the receptor from binding with its ligands. Single dose of Pembrolizumab 200 mg given via intravenous (IV) infusion.
Study: NCT04127578
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 IV pulses administered as concomitant medication over 3 months
Study: NCT04127578
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
Study: NCT01691508
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
Study: NCT01656148
Drug: Fampridine-SR
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
Study: NCT03392792
Drug: tissue plasminogen activator
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA
Study: NCT04201990
Drug: Camrelizumab and Apatinib
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab, iv, Q3W; Apatinib, po, QD
Study: NCT04453436
Drug: Tenofovir Disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Genotipic resistance test
Study: NCT03480568
Drug: Alirocumab 150 MG/ML [Praluent]
Normalized name: alirocumab 150 MG/ML [Praluent]
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cholesterol-lowering therapy
Study: NCT00470054
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01038804
Drug: YM155
Normalized name: Sepantronium bromide
DrugBank: Sepantronium (DB17062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01038804
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT03885427
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: evaluate sedative, and analgesic effects of oral or nebulized ketamine
Study: NCT00193089
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel
Study: NCT00193089
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine
Study: NCT00193089
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab
Study: NCT00134264
Drug: torcetrapib/atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00134264
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01878526
Drug: Alginic acid
Normalized name: Alginic Acid
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algycon 1 tab chew tid after meal
Study: NCT01878526
Drug: placebo (for domperidone)
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (for domperidone) 1 tab oral tid before meal
Study: NCT01878526
Drug: Domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: domperidone (10 mg) 1 tab oral tid before meal
Study: NCT01878526
Drug: placebo (of alginic acid)
Normalized name: Alginic Acid
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (for alginic acid) 1 tab chew tid after meal
Study: NCT03149822
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: tablets Route of administration: oral
Study: NCT03149822
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution Route of administration: injection
Study: NCT01569659
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 80 mg/day for up to 30 weeks
Study: NCT01569659
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Up to 240 mg/day for up to 30 weeks
Study: NCT00049803
Drug: sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00887120
Drug: Lopinavir/ritonavir standard dose According to WHO simplified dosing table
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * BW 6-7.9 kg: 1.5 mL oral q 12 hr~* BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~* BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~* BW \> 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)
Study: NCT00887120
Drug: Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * BW 6-7.9 kg: 1.0 mL oral q 12 hr~* BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~* BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~* BW \> 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)
Study: NCT03345823
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral; Tablet
Study: NCT03345823
Drug: Placebo for Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral; Tablet
Study: NCT00130195
Drug: imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00130195
Drug: daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00130195
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00153803
Drug: Erlotinib (tarceva)
Normalized name: erlotinib Oral Tablet [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
Study: NCT04177290
Drug: Sintilimab (M1b)
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04177290
Drug: Sintilimab (approved)
Normalized name: glucose
DrugBank: Sintilimab (DB15765)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04250064
Drug: Bevacizumab Injection
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Additional concurrent low-dose Bevacizumab with standard EBRT
Study: NCT00862979
Drug: Everolimus (EVR)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
Study: NCT00862979
Drug: cyclosporine A (CyA)
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
Study: NCT00862979
Drug: tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
Study: NCT00130195
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00130195
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04526236
Drug: Methadone Injectable Product
Normalized name: methadone Injectable Product
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative use of placebo for pain management and remifentanil during the surgery.
Study: NCT00862979
Drug: mycophenolate mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
Study: NCT03100903
Drug: BI 655130
Normalized name: Immunoglobulin G1, anti-(human interleukin 36 receptor) (humanized monoclonal BI 655130 gamma1-chain), disulfide with humanized monoclonal BI 655130 kappa-chain, dimer
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT00283699
Drug: albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active drug or placebo dosed bid p o for 8days
Study: NCT02821247
Drug: Aflibercept (Eylea, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection; should comply with the recommendations written in the local Summary of Product Characteristics (SPC) of the product
Study: NCT00517647
Drug: ATMX
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
Study: NCT00433147
Drug: Afegostat tartrate
Normalized name: tartrate
DrugBank: Afegostat (DB04545)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01882647
Drug: 000-0551 Lotion
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01882647
Drug: Vehicle Lotion
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00218530
Drug: Lofexidine
Normalized name: LOFEXIDINE
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01533298
Drug: SmofKabiven peripheral
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenously over 3 days infusion
Study: NCT02757248
Drug: Volasertib
Normalized name: Volasertib
DrugBank: Volasertib (DB12062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib 75-150mg/m2 given intravenously on days 1 and 8
Study: NCT00507949
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.
Study: NCT00867321
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01143727
Drug: Santyl
Normalized name: Santyl
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply one 24-hr period sufficient to cover the wound.
Study: NCT00474110
Drug: Ketamine & hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Detailed Description
Study: NCT03588988
Drug: Dexmedetomidine IV infusion
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
Study: NCT02757248
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
Study: NCT02589496
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg every 3 weeks